Xinlitai: SAL0140 clinical trials for treating chronic kidney disease

Xinliantai's announcement: Recently, the company has received the "Notice of Approval for Clinical Trial" issued by the National Medical Products Administration, approving the company's independently developed innovative small molecule drug SAL0140 tablets to conduct clinical trials for the treatment of chronic kidney disease.